What are the acute management steps and secondary prevention strategies for a patient with suspected intracerebral hemorrhage?

Intracerebral Hemorrhage: Essential Knowledge for Medical Students

Intracerebral hemorrhage (ICH) is a medical emergency requiring immediate recognition and aggressive early management, as 30-50% of patients die within 30 days and early deterioration occurs in over 20% of patients within the first few hours. 1

Epidemiology and Prognosis

• ICH accounts for 10-15% of all strokes with devastating outcomes: 30-day mortality of 35-52%, with half of deaths occurring in the first 2 days 1
• Only 20% of patients achieve functional independence at 6 months 1
• 30-40% of patients experience hematoma expansion, which is a strong predictor of poor outcome 1
• Over 20% of patients experience a decrease in Glasgow Coma Scale (GCS) of ≥2 points between prehospital assessment and emergency department arrival 1

Immediate Diagnosis and Assessment

Initial Evaluation

All patients with suspected ICH must undergo immediate CT or MRI to confirm diagnosis, location, and extent of hemorrhage. 1

• Perform NIHSS on awake/drowsy patients or GCS on obtunded patients as part of initial assessment 1
• Obtain focused history regarding timing of symptom onset and medication history, particularly anticoagulants and antiplatelets 1
• Assess for clinical signs of increased intracranial pressure 1
• Repeat validated neurological scales (e.g., CNS score) at least hourly for the first 24 hours 1

Advanced Imaging

• CT angiography, MR angiography, or catheter angiography is recommended for most patients to exclude underlying lesions such as aneurysms or arteriovenous malformations 1
• CTA can detect the "spot sign" (contrast extravasation), which predicts hematoma expansion, though its sensitivity and positive predictive value are time-dependent and highest within 0-2 hours of onset 1
• Follow-up CT scans at approximately 6 and 24 hours after onset are adequate to exclude hematoma expansion in stable patients 1

Acute Management Priorities

Blood Pressure Management

Blood pressure should be assessed on arrival and every 15 minutes until stabilized, with evidence supporting safety for a target systolic BP <140 mmHg. 1

• Labetalol is recommended as first-line treatment for acute BP management if no contraindications exist 1
• Close BP monitoring (every 30-60 minutes or more frequently if above target) should continue for at least 24-48 hours 1
• After the first 24 hours, continue BP lowering with parenteral or oral antihypertensives to achieve individualized targets for secondary prevention 1
• Avoid excessive BP variability and overshoot, particularly when baseline SBP exceeds 220 mmHg 2

Coagulopathy Reversal

Evaluation must include questions about anticoagulant therapy, measurement of platelet count, PTT, and INR. 1

Warfarin-Associated ICH

• Administer intravenous vitamin K immediately 1
• Prothrombin complex concentrate (PCC), factor IX complex concentrate, or recombinant factor VIIa (rFVIIa) normalize INR rapidly with lower fluid volumes than FFP but carry greater thromboembolism risk 1
• Fresh frozen plasma (FFP) is an alternative but requires greater volumes and longer infusion times 1

Heparin-Associated ICH

• Protamine sulfate should be used to reverse heparin, with dose depending on time from cessation of heparin 1

Direct Oral Anticoagulants (DOACs)

• Specific reversal agents should be used when available 3

Antiplatelet-Associated ICH

• Platelet transfusions for antiplatelet-associated ICH have weak evidence against routine use 4

Thrombolytic-Associated ICH

• Infuse platelets (6-8 units) and cryoprecipitate containing factor VIII to rapidly correct the systemic fibrinolytic state 1

Prevention of Hematoma Expansion

• Risk factors for expansion include: spot sign on CTA, early presentation (<3 hours), anticoagulation use, and initial hematoma volume 1
• Hematoma expansion occurs in 26% of patients at 1 hour and an additional 12% at 20 hours 1
• Expansion after 24 hours is extremely rare (0%), though delayed intraventricular hemorrhage occurs in 21% of patients without initial IVH 1

Surgical Considerations

Indications for Surgery

Surgical intervention should be considered based on location, size, and clinical deterioration. 1

• Cerebellar ICH >15 mL warrants evacuation 4
• Minimally invasive surgery may be considered for supratentorial ICH 4
• External ventricular drainage with intraventricular thrombolysis is recommended for intraventricular extension 4
• Decompressive surgery may be considered for deep supratentorial ICH 4
• Surgical decisions should be made rapidly after coagulation function reversal in anticoagulation-related ICH 3

Secondary Prevention

Long-Term Blood Pressure Control

Blood pressure management is the cornerstone of secondary ICH prevention, with targets generally <130/80 mmHg. 4, 5, 2

• Thiazide diuretics, ACE inhibitors, and angiotensin receptor blockers remain foundational for secondary prevention 2
• Calcium channel blockers are central to acute parenteral therapy 2

Antithrombotic Therapy Resumption

The decision to restart antithrombotic therapy depends on the risk of thromboembolism versus ICH recurrence. 1

• For patients with lower thromboembolic risk (e.g., atrial fibrillation without prior ischemic stroke) and higher amyloid angiopathy risk (elderly with lobar ICH), antiplatelet agents may be preferable to warfarin 1
• In patients with very high thromboembolism risk, warfarin may be restarted at 7-10 days after ICH onset 1
• Antiplatelet therapy for licensed indications has weak evidence for secondary prevention 4

Critical Care Management

Monitoring and Supportive Care

• Patients should be treated on organized stroke units 4
• Intermittent pneumatic compression to prevent proximal deep vein thrombosis is recommended 4
• Prophylactic anti-seizure medications, temperature-lowering measures, prokinetic anti-emetics, and antibiotics have weak evidence against routine use 4
• Temperature and glucose management as single measures (outside care bundles) have weak evidence against routine use 4

Care Bundles

Recent evidence points to ultra-early acute ICH bundles implementing multiple therapies in parallel as the most impactful therapy in reducing morbidity and mortality. 6

• Applying a care bundle has weak evidence supporting its use 4
• It is time for widespread implementation of formalized care bundles in ICH, including specific metrics for time to treatment 6

Common Pitfalls to Avoid

• Do NOT implement general policies that limit treatment within 24 hours of ICH onset 4
• Do NOT use anti-inflammatory drugs outside clinical trials 4
• Do NOT routinely use rFVIIa for hemostasis 4
• Avoid excessive BP lowering that may compromise cerebral perfusion 1, 2
• Do not delay imaging or coagulation reversal in anticoagulated patients 1, 3

Key Prognostic Factors

• Baseline hematoma volume is a strong predictor of outcome but not modifiable 1
• Location matters: 1-year mortality is 51% for deep, 57% for lobar, 42% for cerebellar, and 65% for brainstem ICH 1
• Early neurological deterioration and hematoma expansion independently predict mortality and poor functional outcomes 1